Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer
Author(s)
Connelly, Guinevere G; Kirkland, Orville O; Bohannon, Seven; Lim, Daniel C; Wilson, Robert M; Richards, Edward J; Tay, Dousabel M; Jee, Hyuk; Hellinger, Riley D; Hoang, Ngoc K; Hao, Liang; Chhabra, Arnav; Martin-Alonso, Carmen; Tan, Edward KW; Koehler, Angela N; Yaffe, Michael B; London, Wendy B; Lee, Pui Y; Krammer, Florian; Bohannon, Robert C; Bhatia, Sangeeta N; Sikes, Hadley D; Li, Hojun; ... Show more Show less
DownloadPublished version (2.950Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Neutralizing antibody (NAb) titer is a key biomarker of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but point-of-care methods for assessing NAb titer are not widely available. Here, we present a lateral flow assay that captures SARS-CoV-2 receptor-binding domain (RBD) that has been neutralized from binding angiotensin-converting enzyme 2 (ACE2). Quantification of neutralized RBD in this assay correlates with NAb titer from vaccinated and convalescent patients. This methodology demonstrated superior performance in assessing NAb titer compared with either measurement of total anti-spike immunoglobulin G titer or quantification of the absolute reduction in binding between ACE2 and RBD. Our testing platform has the potential for mass deployment to aid in determining at population scale the degree of protective immunity individuals may have following SARS-CoV-2 vaccination or infection and can enable simple at-home assessment of NAb titer.
Date issued
2022Department
Massachusetts Institute of Technology. Department of BiologyJournal
Cell Reports Methods
Publisher
Elsevier BV
Citation
Connelly, Guinevere G, Kirkland, Orville O, Bohannon, Seven, Lim, Daniel C, Wilson, Robert M et al. 2022. "Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer." Cell Reports Methods, 2 (8).
Version: Final published version